Prophylactic treatment with broadly neutralizing antibody VRC01 selects for escape mutants after infection in Antibody-Mediated Prevention trials
Prophylactic bnAb VRC01 selected for escape mutations in 31% of HIV breakthrough infections, but these mutations were rare in circulating viruses suggesting a fitness cost. More potent bnAbs such as N6 and 1-18 largely retained activity against escape variants.